Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone

Xiao Feng Li; Hao Long Dong; Hong Jiang Wang; Xing Yao Huang; Ye Feng Qiu; Xue Ji; Qing Ye; Chunfeng Li; Yang Liu; Yong Qiang Deng; Tao Jiang; Gong Cheng; Fu Chun Zhang; Andrew D. Davidson; Ya Jun Song; Pei Yong Shi; Cheng Feng Qin

doi:10.1038/s41467-018-02975-w

Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone

Xiao Feng Li, Hao Long Dong, Hong Jiang Wang, Xing Yao Huang, Ye Feng Qiu, Xue Ji, Qing Ye, Chunfeng Li, Yang Liu, Yong Qiang Deng, Tao Jiang, Gong Cheng, Fu Chun Zhang, Andrew D. Davidson, Ya Jun Song, Pei Yong Shi, Cheng Feng Qin^*

^*Corresponding author for this work

Research output: Contribution to journal › Article (Academic Journal) › peer-review

75 Citations (Scopus)

492 Downloads (Pure)

Abstract

The global spread of Zika virus (ZIKV) and its unexpected association with congenital defects necessitates the rapid development of a safe and effective vaccine. Here we report the development and characterization of a recombinant chimeric ZIKV vaccine candidate (termed ChinZIKV) that expresses the prM-E proteins of ZIKV using the licensed Japanese encephalitis live-attenuated vaccine SA14-14-2 as the genetic backbone. ChinZIKV retains its replication activity and genetic stability in vitro, while exhibiting an attenuation phenotype in multiple animal models. Remarkably, immunization of mice and rhesus macaques with a single dose of ChinZIKV elicits robust and long-lasting immune responses, and confers complete protection against ZIKV challenge. Significantly, female mice immunized with ChinZIKV are protected against placental and fetal damage upon ZIKV challenge during pregnancy. Overall, our study provides an alternative vaccine platform in response to the ZIKV emergency, and the safety, immunogenicity, and protection profiles of ChinZIKV warrant further clinical development.

Original language	English
Article number	673
Number of pages	11
Journal	Nature Communications
Volume	9
DOIs	https://doi.org/10.1038/s41467-018-02975-w
Publication status	Published - 14 Feb 2018

Keywords

Live attenuated vaccines
Virology
Infection

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41467-018-02975-w

Full-text PDF (final published version)
This is the final published version of the article (version of record). It first appeared online via Nature at http://www.nature.com/articles/s41467-018-02975-w. Please refer to any applicable terms of use of the publisher.
Final published version, 1.61 MBLicence: CC BY

Handle.net

Persistent link

Cite this

Li, X. F., Dong, H. L., Wang, H. J., Huang, X. Y., Qiu, Y. F., Ji, X., Ye, Q., Li, C., Liu, Y., Deng, Y. Q., Jiang, T., Cheng, G., Zhang, F. C., Davidson, A. D., Song, Y. J., Shi, P. Y., & Qin, C. F. (2018). Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone. Nature Communications, 9, [673]. https://doi.org/10.1038/s41467-018-02975-w

@article{0b4ab4bd86db49f2a467ca9b85faa713,

title = "Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone",

abstract = "The global spread of Zika virus (ZIKV) and its unexpected association with congenital defects necessitates the rapid development of a safe and effective vaccine. Here we report the development and characterization of a recombinant chimeric ZIKV vaccine candidate (termed ChinZIKV) that expresses the prM-E proteins of ZIKV using the licensed Japanese encephalitis live-attenuated vaccine SA14-14-2 as the genetic backbone. ChinZIKV retains its replication activity and genetic stability in vitro, while exhibiting an attenuation phenotype in multiple animal models. Remarkably, immunization of mice and rhesus macaques with a single dose of ChinZIKV elicits robust and long-lasting immune responses, and confers complete protection against ZIKV challenge. Significantly, female mice immunized with ChinZIKV are protected against placental and fetal damage upon ZIKV challenge during pregnancy. Overall, our study provides an alternative vaccine platform in response to the ZIKV emergency, and the safety, immunogenicity, and protection profiles of ChinZIKV warrant further clinical development.",

keywords = "Live attenuated vaccines, Virology , Infection",

author = "Li, {Xiao Feng} and Dong, {Hao Long} and Wang, {Hong Jiang} and Huang, {Xing Yao} and Qiu, {Ye Feng} and Xue Ji and Qing Ye and Chunfeng Li and Yang Liu and Deng, {Yong Qiang} and Tao Jiang and Gong Cheng and Zhang, {Fu Chun} and Davidson, {Andrew D.} and Song, {Ya Jun} and Shi, {Pei Yong} and Qin, {Cheng Feng}",

year = "2018",

month = feb,

day = "14",

doi = "10.1038/s41467-018-02975-w",

language = "English",

volume = "9",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Springer Nature",

}

TY - JOUR

T1 - Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone

AU - Li, Xiao Feng

AU - Dong, Hao Long

AU - Wang, Hong Jiang

AU - Huang, Xing Yao

AU - Qiu, Ye Feng

AU - Ji, Xue

AU - Ye, Qing

AU - Li, Chunfeng

AU - Liu, Yang

AU - Deng, Yong Qiang

AU - Jiang, Tao

AU - Cheng, Gong

AU - Zhang, Fu Chun

AU - Davidson, Andrew D.

AU - Song, Ya Jun

AU - Shi, Pei Yong

AU - Qin, Cheng Feng

PY - 2018/2/14

Y1 - 2018/2/14

N2 - The global spread of Zika virus (ZIKV) and its unexpected association with congenital defects necessitates the rapid development of a safe and effective vaccine. Here we report the development and characterization of a recombinant chimeric ZIKV vaccine candidate (termed ChinZIKV) that expresses the prM-E proteins of ZIKV using the licensed Japanese encephalitis live-attenuated vaccine SA14-14-2 as the genetic backbone. ChinZIKV retains its replication activity and genetic stability in vitro, while exhibiting an attenuation phenotype in multiple animal models. Remarkably, immunization of mice and rhesus macaques with a single dose of ChinZIKV elicits robust and long-lasting immune responses, and confers complete protection against ZIKV challenge. Significantly, female mice immunized with ChinZIKV are protected against placental and fetal damage upon ZIKV challenge during pregnancy. Overall, our study provides an alternative vaccine platform in response to the ZIKV emergency, and the safety, immunogenicity, and protection profiles of ChinZIKV warrant further clinical development.

AB - The global spread of Zika virus (ZIKV) and its unexpected association with congenital defects necessitates the rapid development of a safe and effective vaccine. Here we report the development and characterization of a recombinant chimeric ZIKV vaccine candidate (termed ChinZIKV) that expresses the prM-E proteins of ZIKV using the licensed Japanese encephalitis live-attenuated vaccine SA14-14-2 as the genetic backbone. ChinZIKV retains its replication activity and genetic stability in vitro, while exhibiting an attenuation phenotype in multiple animal models. Remarkably, immunization of mice and rhesus macaques with a single dose of ChinZIKV elicits robust and long-lasting immune responses, and confers complete protection against ZIKV challenge. Significantly, female mice immunized with ChinZIKV are protected against placental and fetal damage upon ZIKV challenge during pregnancy. Overall, our study provides an alternative vaccine platform in response to the ZIKV emergency, and the safety, immunogenicity, and protection profiles of ChinZIKV warrant further clinical development.

KW - Live attenuated vaccines

KW - Virology

KW - Infection

UR - http://www.scopus.com/inward/record.url?scp=85042071353&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-02975-w

DO - 10.1038/s41467-018-02975-w

M3 - Article (Academic Journal)

C2 - 29445153

AN - SCOPUS:85042071353

SN - 2041-1723

VL - 9

JO - Nature Communications

JF - Nature Communications

M1 - 673

ER -

Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone

Abstract

Keywords

UN SDGs

Access to Document

Handle.net

Other files and links

Fingerprint

ANALYSIS OF DENGUE VIRUS NS5 PROTEIN - HOST CELL INTERACTIONS

Professor Andrew D Davidson

Cite this

Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone

Abstract

Keywords

UN SDGs

Access to Document

Handle.net

Other files and links

Fingerprint

Projects

ANALYSIS OF DENGUE VIRUS NS5 PROTEIN - HOST CELL INTERACTIONS

Profiles

Professor Andrew D Davidson

Cite this